Report Overview

The global Central Nervous System (CNS) therapeutics market size stood at around USD 91.67 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The global CNS therapeutics market is likely to be driven by the rise in ageing population. According to the National Institute on Aging, almost 524 million individuals, approximately 8% of the global population, were above the age of 65 in 2010. This number is expected to reach 1.5 billion, which is almost 16% of the global population, by 2050. The rate of incidence of CNS diseases increases with advancing age. Governments as well as non-government organizations across the globe are taking various initiatives to raise awareness about CNS disorders. Organizations are also raising funds to support clinical research & development for better treatment of the disease.



Market Drivers

The global CNS therapeutics market is likely to be driven by the high prevalence of these disorders, and growth in the awareness about CNS therapeutics diseases. Unmet needs for the treatment of CNS disease are high. In order to fuel research and clinical developments in these disorders, governments, non-profit organizations, and pharmaceutical and biotechnology companies across the globe have allocated and increased their research funding budget over a period of time. This factor is expected to fuel the market growth during the forecast period.

Patent expiry of drugs, however, is likely to affect the overall market growth during the forecast period.

Major Central Nervous System Disease

The mental health segment dominated the market in 2019 and is expected to continue its dominance throughout the forecast period. An increasing number of patients with mental disorders, extensive R&D, a rising number of rehabilitation facilities, and the introduction of novel treatment procedures are prime factors propelling growth. R&D and the introduction of novel and advanced solutions for neurological imaging are spurring the growth of the neurovascular diseases segment.